Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SGMO

SGMO - Sangamo Therapeutics Inc Stock Price, Fair Value and News

0.64USD+0.03 (+4.92%)Delayed

Market Summary

SGMO
USD0.64+0.03
Delayed
4.92%

SGMO Stock Price

View Fullscreen

SGMO RSI Chart

SGMO Valuation

Market Cap

132.8M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

0.75

EV/EBITDA

-0.24

Price/Free Cashflow

-0.61

SGMO Price/Sales (Trailing)

SGMO Profitability

EBT Margin

-189.08%

Return on Equity

-578.61%

Return on Assets

-254.38%

Free Cashflow Yield

-164.27%

SGMO Fundamentals

SGMO Revenue

Revenue (TTM)

176.2M

Rev. Growth (Yr)

-92.5%

Rev. Growth (Qtr)

-78.27%

SGMO Earnings

Earnings (TTM)

-328.1M

Earnings Growth (Yr)

-332.29%

Earnings Growth (Qtr)

18.59%

Breaking Down SGMO Revenue

Last 7 days

14.3%

Last 30 days

23.1%

Last 90 days

-53.6%

Trailing 12 Months

-50.4%

How does SGMO drawdown profile look like?

SGMO Financial Health

Current Ratio

1.71

SGMO Investor Care

Shares Dilution (1Y)

20.77%

Diluted EPS (TTM)

-1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023241.0M218.5M201.4M176.2M
2022112.7M114.2M112.1M111.3M
2021131.4M137.7M108.5M110.7M
2020107.4M111.4M147.2M118.2M
201979.9M76.0M74.4M102.4M
201845.8M58.9M70.7M84.5M
201718.9M23.4M32.4M36.6M
201630.0M25.3M19.6M19.4M
201551.2M49.2M45.4M39.5M
201427.6M31.1M37.8M45.9M
201323.0M25.4M26.2M24.1M
201211.4M14.4M17.5M21.7M
201116.4M11.3M10.3M10.3M
2010021.7M21.3M20.8M
200900022.2M

Tracking the Latest Insider Buys and Sells of Sangamo Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 25, 2024
duraibabu prathyusha
sold (taxes)
-3,901
1.13
-3,453
svp, chief financial officer
Feb 25, 2024
pooler amy
sold (taxes)
-2,778
1.13
-2,459
vp, head of research
Feb 25, 2024
macrae sandy
sold (taxes)
-27,297
1.13
-24,157
president, ceo and director
Feb 25, 2024
willoughby scott b.
sold (taxes)
-3,901
1.13
-3,453
svp, gen. counsel & secretary
Feb 25, 2024
dubois-stringfellow nathalie
sold (taxes)
-5,661
1.13
-5,010
svp-chief development officer
Feb 24, 2024
willoughby scott b.
sold (taxes)
-4,948
1.13
-4,379
svp, gen. counsel & secretary
Feb 24, 2024
macrae sandy
sold (taxes)
-18,209
1.13
-16,115
president, ceo and director
Feb 24, 2024
dubois-stringfellow nathalie
sold (taxes)
-6,185
1.13
-5,474
svp-chief development officer
Feb 24, 2024
pooler amy
sold (taxes)
-2,496
1.13
-2,209
vp, head of research
Feb 24, 2024
duraibabu prathyusha
sold (taxes)
-6,185
1.13
-5,474
svp, chief financial officer

1–10 of 50

Which funds bought or sold SGMO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
unchanged
-
3,173
16,755
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-3,284
10,038
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-74.98
-51,850
23,146
-%
May 15, 2024
Royal Bank of Canada
reduced
-89.39
-27,000
5,000
-%
May 15, 2024
MARSHALL WACE, LLP
new
-
247,059
247,059
-%
May 15, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC
reduced
-80.96
-419,036
128,644
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-1.58
130,581
740,489
-%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-24.64
-11,289
148,985
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
new
-
20,359
20,359
-%
May 15, 2024
D. E. Shaw & Co., Inc.
reduced
-34.51
-489,007
2,055,800
-%

1–10 of 46

Are Funds Buying or Selling SGMO?

Are funds buying SGMO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SGMO
No. of Funds

Unveiling Sangamo Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 05, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 13, 2024
vanguard group inc
7.10%
12,598,994
SC 13G/A
Feb 12, 2024
biogen inc.
75%
14,652,466
SC 13G/A
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
14,095,865
SC 13G/A
Jan 22, 2024
state street corp
1.53%
2,708,368
SC 13G/A
Oct 10, 2023
wasatch advisors lp
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.57%
14,045,609
SC 13G/A
Feb 09, 2023
wasatch advisors inc
-
0
SC 13G/A
Feb 07, 2023
state street corp
5.97%
9,788,884
SC 13G/A

Recent SEC filings of Sangamo Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
Apr 30, 2024
8-K
Current Report
Apr 19, 2024
ARS
ARS
Apr 19, 2024
DEF 14A
DEF 14A
Apr 05, 2024
SC 13G/A
Major Ownership Report
Apr 03, 2024
PRE 14A
PRE 14A
Mar 25, 2024
424B5
Prospectus Filed
Mar 25, 2024
8-K
Current Report
Mar 13, 2024
10-K
Annual Report

Peers (Alternatives to Sangamo Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Sangamo Therapeutics Inc News

Latest updates
MarketBeat20 hours ago
Zacks Investment Research10 May 202402:23 am

Sangamo Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-2,042,0009,398,0006,835,000157,957,00027,230,00026,460,00029,378,00028,231,00027,986,00028,563,00027,872,00026,280,00025,800,00057,763,00021,553,00013,076,00054,851,00021,958,00017,548,0008,071,000
Operating Expenses-18.9%52,007,00064,101,000115,806,000130,407,000139,923,00082,622,00081,354,00075,112,00073,492,00067,885,00076,999,00076,572,00072,582,00069,232,00061,464,00059,450,00057,598,00053,382,00051,206,00051,052,00051,968,000
  S&GA Expenses-100.0%-13,099,00013,918,00016,014,00018,136,00016,443,00016,238,00015,093,00014,908,00016,084,00014,501,00016,486,00016,148,00016,874,00016,177,00017,927,00016,119,00015,053,00014,918,00014,597,00017,118,000
  R&D Expenses-29.2%35,891,00050,706,00057,089,00063,046,00063,216,00066,179,00065,116,00060,019,00058,584,00051,801,00062,498,00060,086,00056,434,00052,358,00045,287,00041,523,00041,479,00038,329,00036,288,00036,455,00034,850,000
EBITDA Margin-29.2%-1.82-1.41-1.18-0.87-0.47-1.61-1.49-1.46-1.49-1.52-1.04-0.82---------
Income Taxes136.0%98,000-272,0001,270,000-6,264,000194,000238,00030,00082,000100,000-73,500100,00024,000262,000108,000237,000------
Earnings Before Taxes19.1%-48,991,000-60,567,000-102,893,000-120,770,00021,327,000-51,714,000-53,125,000-43,091,000-43,919,000------------
EBT Margin-26.7%-1.89-1.49-1.26-0.94-0.53-1.72-1.59-1.56-1.58-1.61-1.11-0.88---------
Net Income18.6%-49,089,000-60,295,000-104,163,000-114,506,00021,133,000-51,973,000-53,155,000-43,173,000-43,977,000-37,488,000-47,688,000-47,174,000-45,933,000-40,604,000-1,550,000-35,929,000-42,913,0004,555,000-27,307,000-30,284,000-42,150,000
Net Income Margin-27.2%-1.86-1.46-1.24-0.91-0.53-1.73-1.59-1.51-1.57-1.61-1.67-0.98---------
Free Cashflow8.5%-48,663,000-53,209,000-50,037,000-66,251,000-76,500,000-64,523,000-58,031,000-59,430,000-61,814,000-55,572,000-64,627,000-59,830,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-22.0%129165220325441563594617654722772835877939964895584638640673543
  Current Assets-27.2%69.0094.00148160227300337343340399447554607660700679371405384462363
    Cash Equivalents22.4%55.0045.0057.0067.0078.0010095.0011812018017717012313325946786.0082.0011416981.00
  Net PPE-18.1%22.0027.0028.0061.0060.0064.0056.0053.0052.0052.0051.0050.0045.0041.0035.0034.0031.0030.0027.0021.0018.00
  Goodwill------38.0035.0037.0039.0040.0041.0042.0041.0043.0041.0039.0039.0039.0038.0040.0039.00
Liabilities-12.3%72.0082.0085.0091.00105268285299320347366390408441443383190205221228214
  Current Liabilities-15.7%40.0048.0048.0054.0058.0011212212011912813213713314412494.0062.0070.0081.0082.0091.00
Shareholder's Equity-31.6%57.0083.00135234336295309318335375406445469497521511394433419446329
  Retained Earnings-3.5%-1,455-1,406-1,346-1,241-1,127-1,148-1,096-1,043-1,000-956-918-871-823-777-737-735-699-656-661-634-603
  Additional Paid-In Capital1.6%1,5161,4921,4861,4801,4671,4501,4231,3731,3401,3341,3241,3131,2921,2691,2561,2481,0971,0911,0841,079934
Shares Outstanding1.2%180178177174169167151147146145145144---------
Minority Interest--------------0.94-0.87-0.53-0.250.000.000.001.001.00
Float----229---633---1,734---1,262---1,245-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations3.7%-48,663-50,538-47,293-60,711-66,300-57,049-53,618-53,985-58,975-52,714-59,420-52,567-68,550-4,29533,067159,993-18,890-20,816-38,874-39,593-45,119
  Share Based Compensation-55.5%2,7196,1076,1896,7908,2778,2487,7937,9187,6918,0767,8739,4837,5246,6426,6826,7645,6205,2394,7014,8674,523
Cashflow From Investing-5.0%35,84037,70837,62742,46835,72842,613-13,46228,4291,70552,63560,97689,29945,289-130,458-242,49777,60823,720-16,402-16,217-12,383-14,799
Cashflow From Financing13146.7%22,122167-1006,5198,00219,53543,81822,874-1,5672,1125,49210,01915,2356,9191,616144,1564091,219704139,890216
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SGMO Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenues$ 481$ 157,957
Operating expenses:  
Research and development35,89163,216
General and administrative11,76718,136
Impairment of long-lived assets4,34920,433
Impairment of goodwill038,138
Total operating expenses52,007139,923
(Loss) income from operations(51,526)18,034
Interest and other income, net2,5353,293
(Loss) income before income taxes(48,991)21,327
Income tax expense98194
Net (loss) income$ (49,089)$ 21,133
Net (loss) income per share  
Basic (in dollars per share)$ (0.27)$ 0.13
Diluted (in dollars per share)$ (0.27)$ 0.12
Shares used in computing net (loss) income per share  
Basic (in shares)180,342168,533
Diluted (in shares)180,342169,181

SGMO Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 54,417$ 45,204
Restricted cash9160
Marketable securities035,798
Accounts receivable691923
Prepaid expenses and other current assets12,61212,403
Total current assets68,63694,328
Property and equipment, net22,01726,874
Operating lease right-of-use assets20,93525,991
Refundable research income tax credits and other non-current assets17,37316,627
Restricted cash01,500
Total assets128,961165,320
Current liabilities:  
Accounts payable15,46815,259
Accrued compensation and employee benefits6,3008,918
Other accrued liabilities18,47423,554
Total current liabilities40,24247,731
Long-term portion of lease liabilities30,81733,515
Other non-current liabilities1,2051,187
Total liabilities72,26482,433
Commitments and contingencies
Stockholders’ equity:  
Preferred stock00
Common stock2,0371,781
Additional paid-in capital1,515,9261,492,077
Accumulated deficit(1,455,465)(1,406,376)
Accumulated other comprehensive loss(5,801)(4,595)
Total stockholders’ equity56,69782,887
Total liabilities and stockholders’ equity$ 128,961$ 165,320
SGMO
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
 CEO
 WEBSITEsangamo.com
 INDUSTRYBiotechnology
 EMPLOYEES478

Sangamo Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Sangamo Therapeutics Inc? What does SGMO stand for in stocks?

SGMO is the stock ticker symbol of Sangamo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sangamo Therapeutics Inc (SGMO)?

As of Fri May 17 2024, market cap of Sangamo Therapeutics Inc is 132.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers. The fair value of Sangamo Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sangamo Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sangamo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SGMO is over valued or under valued. Whether Sangamo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sangamo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGMO.

What is Sangamo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SGMO's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 0.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sangamo Therapeutics Inc's stock?

In the past 10 years, Sangamo Therapeutics Inc has provided -0.26 (multiply by 100 for percentage) rate of return.